Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 689

1.

The impact of high functional connectivity network hub resection on language task performance in adult low- and high-grade glioma.

Lee AT, Faltermeier C, Morshed RA, Young JS, Kakaizada S, Valdivia C, Findlay AM, Tarapore PE, Nagarajan SS, Hervey-Jumper SL, Berger MS.

J Neurosurg. 2020 Apr 3:1-11. doi: 10.3171/2020.1.JNS192267. [Epub ahead of print]

PMID:
32244221
2.

Quantifying eloquent locations for glioblastoma surgery using resection probability maps.

Müller DMJ, Robe PA, Ardon H, Barkhof F, Bello L, Berger MS, Bouwknegt W, Van den Brink WA, Conti Nibali M, Eijgelaar RS, Furtner J, Han SJ, Hervey-Jumper SL, Idema AJS, Kiesel B, Kloet A, De Munck JC, Rossi M, Sciortino T, Vandertop WP, Visser M, Wagemakers M, Widhalm G, Witte MG, Zwinderman AH, De Witt Hamer PC.

J Neurosurg. 2020 Apr 3:1-11. doi: 10.3171/2020.1.JNS193049. [Epub ahead of print]

PMID:
32244208
3.

Letter: The Coronavirus Disease 2019 Global Pandemic: A Neurosurgical Treatment Algorithm.

Burke JF, Chan AK, Mummaneni V, Chou D, Lobo EP, Berger MS, Theodosopoulos PV, Mummaneni PV.

Neurosurgery. 2020 Apr 3. pii: nyaa116. doi: 10.1093/neuros/nyaa116. [Epub ahead of print] No abstract available.

PMID:
32242901
4.

Principles of Supplemental Motor Area and Cingulate Tumor Resection With Asleep Trimodal Motor Mapping: 2-Dimensional Operative Video.

Magill ST, Rubio RR, Berger MS.

Oper Neurosurg (Hagerstown). 2020 Mar 13. pii: opaa036. doi: 10.1093/ons/opaa036. [Epub ahead of print]

PMID:
32167140
5.

MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.

Mathur R, Zhang Y, Grimmer MR, Hong C, Zhang M, Bollam S, Petrecca K, Clarke J, Berger MS, Phillips JJ, Oberheim-Bush NA, Molinaro AM, Chang SM, Costello JF.

Neuro Oncol. 2020 Mar 13. pii: noaa059. doi: 10.1093/neuonc/noaa059. [Epub ahead of print]

PMID:
32166314
6.

Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features.

Sloan EA, Hilz S, Gupta R, Cadwell C, Ramani B, Hofmann J, Kline CN, Banerjee A, Reddy A, Oberheim Bush NA, Chang S, Braunstein S, Chang EF, Raffel C, Gupta N, Sun PP, Kim JYH, Moes G, Alva E, Li R, Bruggers CS, Alashari M, Wetmore C, Garg S, Dishop M, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Phillips JJ, Pekmezci M, Tihan T, Bollen AW, Berger MS, Costello JF, Perry A, Solomon DA.

Acta Neuropathol. 2020 Mar 10. doi: 10.1007/s00401-020-02144-8. [Epub ahead of print] No abstract available.

PMID:
32157385
7.

High Interobserver Agreement in the Subjective Classification of 5-Aminolevulinic Acid Fluorescence Levels in Newly Diagnosed Glioblastomas.

Mischkulnig M, Kiesel B, Borkovec M, Wadiura LI, Benner D, Hosmann A, Hervey-Jumper S, Knosp E, Roessler K, Berger MS, Widhalm G.

Lasers Surg Med. 2020 Mar 8. doi: 10.1002/lsm.23228. [Epub ahead of print]

PMID:
32147864
8.

Sideline Concussion Assessment: The Current State of the Art.

Yue JK, Phelps RRL, Chandra A, Winkler EA, Manley GT, Berger MS.

Neurosurgery. 2020 Mar 3. pii: nyaa023. doi: 10.1093/neuros/nyaa022. [Epub ahead of print]

PMID:
32126135
9.

The Path to U.S. Neurosurgical Residency for Foreign Medical Graduates: Trends from a Decade 2007-2017.

Chandra A, Brandel MG, Wadhwa H, Almeida ND, Yue JK, Nuru MO, Cheng J, Lu S, Patel A, Essayed W, McDermott MW, Berger MS, Aghi MK.

World Neurosurg. 2020 Feb 19. pii: S1878-8750(20)30344-2. doi: 10.1016/j.wneu.2020.02.069. [Epub ahead of print]

PMID:
32084618
10.

Influence of Corticosteroids and Antiepileptic Drugs on Visible 5-Aminolevulinic Acid Fluorescence in a Series of Initially Suspected Low-Grade Gliomas Including World Health Organization Grade II, III, and IV Gliomas.

Wadiura LI, Mischkulnig M, Hosmann A, Borkovec M, Kiesel B, Rötzer T, Mercea PA, Furtner J, Hervey-Jumper S, Rössler K, Berger MS, Widhalm G.

World Neurosurg. 2020 Feb 8. pii: S1878-8750(20)30261-8. doi: 10.1016/j.wneu.2020.01.243. [Epub ahead of print]

PMID:
32045726
11.

Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.

Molinaro AM, Hervey-Jumper S, Morshed RA, Young J, Han SJ, Chunduru P, Zhang Y, Phillips JJ, Shai A, Lafontaine M, Crane J, Chandra A, Flanigan P, Jahangiri A, Cioffi G, Ostrom Q, Anderson JE, Badve C, Barnholtz-Sloan J, Sloan AE, Erickson BJ, Decker PA, Kosel ML, LaChance D, Eckel-Passow J, Jenkins R, Villanueva-Meyer J, Rice T, Wrensch M, Wiencke JK, Oberheim Bush NA, Taylor J, Butowski N, Prados M, Clarke J, Chang S, Chang E, Aghi M, Theodosopoulos P, McDermott M, Berger MS.

JAMA Oncol. 2020 Feb 6. doi: 10.1001/jamaoncol.2019.6143. [Epub ahead of print]

PMID:
32027343
12.

Introduction. Advances and future directions in brain mapping in neurosurgery.

Golby AJ, Leuthardt EC, Duffau H, Berger MS.

Neurosurg Focus. 2020 Feb 1;48(2):E1. doi: 10.3171/2019.11.FOCUS19880. No abstract available.

PMID:
32006943
13.

Advancing neuro-oncology of glial tumors from big data and multidisciplinary studies.

Lin CA, Berger MS.

J Neurooncol. 2020 Jan;146(1):1-7. doi: 10.1007/s11060-019-03369-8. Epub 2019 Dec 18. Review.

PMID:
31853838
14.

The neurosurgery applicant's "arms race": analysis of medical student publication in the Neurosurgery Residency Match.

Wadhwa H, Shah SS, Shan J, Cheng J, Beniwal AS, Chen JS, Gill SA, Mummaneni N, McDermott MW, Berger MS, Aghi MK.

J Neurosurg. 2019 Nov 1:1-9. doi: 10.3171/2019.8.JNS191256. [Epub ahead of print]

PMID:
31675693
15.

Management of Glioblastoma, Present and Future.

Oberheim Bush NA, Hervey-Jumper SL, Berger MS.

World Neurosurg. 2019 Nov;131:328-338. doi: 10.1016/j.wneu.2019.07.044.

PMID:
31658576
16.

An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.

Gittleman H, Cioffi G, Chunduru P, Molinaro AM, Berger MS, Sloan AE, Barnholtz-Sloan JS.

Neurooncol Adv. 2019 May-Dec;1(1):vdz007. doi: 10.1093/noajnl/vdz007. Epub 2019 May 30.

17.

Patient safety movement in neurological surgery: the current state and future directions.

Sankaran S, Andrews JP, Chicas M, Wachter RM, Berger MS.

J Neurosurg. 2019 Oct 4:1-11. doi: 10.3171/2019.7.JNS191505. [Epub ahead of print] No abstract available.

PMID:
31585429
18.

Disruption of Frontal Aslant Tract Is Not Associated with Long-Term Postoperative Language Deficits.

Young JS, Morshed RA, Mansoori Z, Cha S, Berger MS.

World Neurosurg. 2020 Jan;133:192-195. doi: 10.1016/j.wneu.2019.09.128. Epub 2019 Sep 28.

PMID:
31574328
19.

Impact of facility type and volume in low-grade glioma outcomes.

Zhu P, Du XL, Blanco AI, Ballester LY, Tandon N, Berger MS, Zhu JJ, Esquenazi Y.

J Neurosurg. 2019 Sep 27:1-11. doi: 10.3171/2019.6.JNS19409. [Epub ahead of print]

PMID:
31561219
20.

Supracerebellar Approach to Radiation-Induced Giant Capillary Telangiectasia Within Juvenile Pilocytic Astrocytoma of Upper Brainstem.

Rubio RR, Chae R, Khare A, Dubnicoff T, Winkler E, Sloan E, Bollen AW, Berger MS, Abla AA.

World Neurosurg. 2019 Dec;132:57. doi: 10.1016/j.wneu.2019.08.172. Epub 2019 Aug 31.

PMID:
31479784
21.

From bench to bedside: trends in National Institutes of Health funding for neurosurgeons from 1991 to 2015.

Jahangiri A, Flanigan PM, Arnush M, Chandra A, Rick JW, Choi S, Chou A, Berger MS, Aghi MK.

J Neurosurg. 2019 Aug 30:1-10. doi: 10.3171/2019.1.JNS181531. [Epub ahead of print]

PMID:
31470404
22.

Driving Neuronal Differentiation through Reversal of an ERK1/2-miR-124-SOX9 Axis Abrogates Glioblastoma Aggressiveness.

Sabelström H, Petri R, Shchors K, Jandial R, Schmidt C, Sacheva R, Masic S, Yuan E, Fenster T, Martinez M, Saxena S, Nicolaides TP, Ilkhanizadeh S, Berger MS, Snyder EY, Weiss WA, Jakobsson J, Persson AI.

Cell Rep. 2019 Aug 20;28(8):2064-2079.e11. doi: 10.1016/j.celrep.2019.07.071.

23.

Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors.

Dawicki W, Allen KJH, Jiao R, Malo ME, Helal M, Berger MS, Ludwig DL, Dadachova E.

Oncoimmunology. 2019 May 1;8(8):1607673. doi: 10.1080/2162402X.2019.1607673. eCollection 2019.

24.

Management of low-grade glioma: a systematic review and meta-analysis.

Brown TJ, Bota DA, van Den Bent MJ, Brown PD, Maher E, Aregawi D, Liau LM, Buckner JC, Weller M, Berger MS, Glantz M.

Neurooncol Pract. 2019 Jul;6(4):249-258. doi: 10.1093/nop/npy034. Epub 2018 Aug 18. Review.

PMID:
31386075
25.

Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM.

McKinney A, Lindberg OR, Engler JR, Chen KY, Kumar A, Gong H, Lu KV, Simonds EF, Cloughesy TF, Liau LM, Prados M, Bollen AW, Berger MS, Shieh JTC, James CD, Nicolaides TP, Yong WH, Lai A, Hegi ME, Weiss WA, Phillips JJ.

Mol Cancer Ther. 2019 Sep;18(9):1565-1576. doi: 10.1158/1535-7163.MCT-18-1330. Epub 2019 Jul 3.

26.

Insurance type impacts the economic burden and survival of patients with newly diagnosed glioblastoma.

Chandra A, Young JS, Dalle Ore C, Dayani F, Lau D, Wadhwa H, Rick JW, Nguyen AT, McDermott MW, Berger MS, Aghi MK.

J Neurosurg. 2019 Jun 21:1-11. doi: 10.3171/2019.3.JNS182629. [Epub ahead of print]

PMID:
31226687
27.

The value of visible 5-ALA fluorescence and quantitative protoporphyrin IX analysis for improved surgery of suspected low-grade gliomas.

Widhalm G, Olson J, Weller J, Bravo J, Han SJ, Phillips J, Hervey-Jumper SL, Chang SM, Roberts DW, Berger MS.

J Neurosurg. 2019 May 10:1-10. doi: 10.3171/2019.1.JNS182614. [Epub ahead of print]

PMID:
31075771
28.

The management of low-grade gliomas in adults.

Morshed RA, Young JS, Hervey-Jumper SL, Berger MS.

J Neurosurg Sci. 2019 Aug;63(4):450-457. doi: 10.23736/S0390-5616.19.04701-5. Epub 2019 Mar 27. Review.

PMID:
30916536
29.

Delirium Risk Factors and Associated Outcomes in a Neurosurgical Cohort: A Case-Control Study.

Morshed RA, Young JS, Safaee M, Sankaran S, Berger MS, McDermott MW, Hervey-Jumper SL.

World Neurosurg. 2019 Jun;126:e930-e936. doi: 10.1016/j.wneu.2019.03.012. Epub 2019 Mar 11.

PMID:
30872201
30.

High density is a property of slow-cycling and treatment-resistant human glioblastoma cells.

Sabelström H, Quigley DA, Fenster T, Foster DJ, Fuchshuber CAM, Saxena S, Yuan E, Li N, Paterno F, Phillips JJ, James CD, Norling B, Berger MS, Persson AI.

Exp Cell Res. 2019 May 1;378(1):76-86. doi: 10.1016/j.yexcr.2019.03.003. Epub 2019 Mar 5.

31.

Roles of ventral versus dorsal pathways in language production: An awake language mapping study.

Ries SK, Piai V, Perry D, Griffin S, Jordan K, Henry R, Knight RT, Berger MS.

Brain Lang. 2019 Apr;191:17-27. doi: 10.1016/j.bandl.2019.01.001. Epub 2019 Feb 12.

32.

Comparing Glioblastoma Surgery Decisions Between Teams Using Brain Maps of Tumor Locations, Biopsies, and Resections.

Müller DMJ, Robe PAJT, Eijgelaar RS, Witte MG, Visser M, de Munck JC, Broekman MLD, Seute T, Hendrikse J, Noske DP, Vandertop WP, Barkhof F, Kouwenhoven MCM, Mandonnet E, Berger MS, De Witt Hamer PC.

JCO Clin Cancer Inform. 2019 Jan;3:1-12. doi: 10.1200/CCI.18.00089.

33.

Erratum. Obituary. Charles B. Wilson, MD, 1929-2018.

Berger MS.

J Neurosurg. 2019 Jan 11;130(3):1022. doi: 10.3171/2018.12.JNS18974a. No abstract available.

PMID:
30641846
34.

Insular glioma surgery: an evolution of thought and practice.

Hervey-Jumper SL, Berger MS.

J Neurosurg. 2019 Jan 1;130(1):9-16. doi: 10.3171/2018.10.JNS181519. Review.

PMID:
30611160
35.

Evaluation of Three Morphologically Distinct Virus-Like Particles as Nanocarriers for Convection-Enhanced Drug Delivery to Glioblastoma.

Finbloom JA, Aanei IL, Bernard JM, Klass SH, Elledge SK, Han K, Ozawa T, Nicolaides TP, Berger MS, Francis MB.

Nanomaterials (Basel). 2018 Dec 5;8(12). pii: E1007. doi: 10.3390/nano8121007.

36.

MEG imaging of recurrent gliomas reveals functional plasticity of hemispheric language specialization.

Traut T, Sardesh N, Bulubas L, Findlay A, Honma SM, Mizuiri D, Berger MS, Hinkley LB, Nagarajan SS, Tarapore PE.

Hum Brain Mapp. 2019 Mar;40(4):1082-1092. doi: 10.1002/hbm.24430. Epub 2018 Dec 13.

PMID:
30549134
37.

Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60.

Morshed RA, Han SJ, Hervey-Jumper SL, Pekmezci M, Troncon I, Chang SM, Butowski NA, Berger MS.

J Neurooncol. 2019 Jan;141(2):383-391. doi: 10.1007/s11060-018-03044-4. Epub 2018 Nov 29.

PMID:
30498891
38.

Obituary. Charles B. Wilson, MD, 1929-2018.

Berger MS, Garner IV, McDermott MW.

J Neurosurg. 2018 Aug 1;129(2):547-550. doi: 10.3171/2018.5.JNS18974. No abstract available. Erratum in: J Neurosurg. 2019 Jan 11;130(3):1022.

PMID:
30485247
39.

Evidence for Improving Outcome Through Extent of Resection.

Hervey-Jumper SL, Berger MS.

Neurosurg Clin N Am. 2019 Jan;30(1):85-93. doi: 10.1016/j.nec.2018.08.005. Epub 2018 Nov 1. Review.

PMID:
30470408
40.

Presence of Histopathological Treatment Effects at Resection of Recurrent Glioblastoma: Incidence and Effect on Outcome.

Dalle Ore CL, Chandra A, Rick J, Lau D, Shahin M, Nguyen AT, McDermott M, Berger MS, Aghi MK.

Neurosurgery. 2019 Dec 1;85(6):793-800. doi: 10.1093/neuros/nyy501.

PMID:
30445646
41.

Commentary: Deficiencies in Socioeconomic Training During Neurosurgical Training.

Karsy M, Park MS, Bekelis K, Braca JA 3rd, Nahed BV, Colen CB, Barbaro NM, Berger MS, Mukherjee D.

Neurosurgery. 2019 Jan 1;84(1):E79-E85. doi: 10.1093/neuros/nyy482. No abstract available.

PMID:
30445444
42.

Preoperative Resectability Estimates of Nonenhancing Glioma by Neurosurgeons and a Resection Probability Map.

Hendriks EJ, Idema S, Hervey-Jumper SL, Bernat AL, Zwinderman AH, Barkhof F, Vandertop WP, Mandonnet E, Duffau H, Berger MS, De Witt Hamer PC.

Neurosurgery. 2019 Aug 1;85(2):E304-E313. doi: 10.1093/neuros/nyy487.

PMID:
30423155
43.

Perioperative outcomes following reoperation for recurrent insular gliomas.

Morshed RA, Young JS, Han SJ, Hervey-Jumper SL, Berger MS.

J Neurosurg. 2018 Sep 21;131(2):467-473. doi: 10.3171/2018.4.JNS18375.

PMID:
30239317
44.

Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma.

Taylor JW, Parikh M, Phillips JJ, James CD, Molinaro AM, Butowski NA, Clarke JL, Oberheim-Bush NA, Chang SM, Berger MS, Prados M.

J Neurooncol. 2018 Nov;140(2):477-483. doi: 10.1007/s11060-018-2977-3. Epub 2018 Aug 27.

45.

Subcortical stimulation mapping of descending motor pathways for perirolandic gliomas: assessment of morbidity and functional outcome in 702 cases.

Han SJ, Morshed RA, Troncon I, Jordan KM, Henry RG, Hervey-Jumper SL, Berger MS.

J Neurosurg. 2018 Aug 17;131(1):201-208. doi: 10.3171/2018.3.JNS172494.

PMID:
30117770
46.

5-Aminolevulinic acid fluorescence guided surgery for recurrent high-grade gliomas.

Chohan MO, Berger MS.

J Neurooncol. 2019 Feb;141(3):517-522. doi: 10.1007/s11060-018-2956-8. Epub 2018 Aug 10. Review.

PMID:
30097823
47.

Interfacility neurosurgical transfers: an analysis of nontraumatic inpatient and emergency department transfers with implications for improvements in care.

Safaee MM, Morshed RA, Spatz J, Sankaran S, Berger MS, Aghi MK.

J Neurosurg. 2018 Aug 3;131(1):281-289. doi: 10.3171/2018.3.JNS173224.

PMID:
30074453
48.

The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.

Phillips JJ, Gong H, Chen K, Joseph NM, van Ziffle J, Bastian BC, Grenert JP, Kline CN, Mueller S, Banerjee A, Nicolaides T, Gupta N, Berger MS, Lee HS, Pekmezci M, Tihan T, Bollen AW, Perry A, Shieh JTC, Solomon DA.

Brain Pathol. 2019 Jan;29(1):85-96. doi: 10.1111/bpa.12639. Epub 2018 Nov 6.

PMID:
30051528
49.

Disparities in health care determine prognosis in newly diagnosed glioblastoma.

Chandra A, Rick JW, Dalle Ore C, Lau D, Nguyen AT, Carrera D, Bonte A, Molinaro AM, Theodosopoulos PV, McDermott MW, Berger MS, Aghi MK.

Neurosurg Focus. 2018 Jun;44(6):E16. doi: 10.3171/2018.3.FOCUS1852.

50.

Safety and outcomes of resection of butterfly glioblastoma.

Dayani F, Young JS, Bonte A, Chang EF, Theodosopoulos P, McDermott MW, Berger MS, Aghi MK.

Neurosurg Focus. 2018 Jun;44(6):E4. doi: 10.3171/2018.3.FOCUS1857.

PMID:
29852771

Supplemental Content

Loading ...
Support Center